Concurrent EGFR and KRAS mutations in non-small cell lung cancer: Challenging the paradigm of linear targeted therapy. Journal of Current Biomedical Reports, [S. l.], v. 6, n. 2, p. 45–46, 2025. DOI: 10.61882/jcbior.6.2.299. Disponível em: https://mail.jcbior.com/index.php/JCBioR/article/view/299. Acesso em: 6 jun. 2026.